AWM Investment Company Inc. Boosts Stock Holdings in Progyny, Inc. $PGNY

Key Points

• AWM Investment Company Inc. increased its stake in Progyny by 12.5%, now holding 180,000 shares worth approximately $4.02 million.
• Progyny's stock recently decreased by 1.1%, trading at $23.41, with a market cap of $2.01 billion and a P/E ratio of 39.68.
• Despite missing earnings expectations, Progyny reported a revenue increase of 9.5% year-over-year and has received upgrades from various analysts, setting target prices up to $28.00.

AWM Investment Company Inc. lifted its holdings in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 12.5% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 180,000 shares of the company's stock after buying an additional 20,000 shares during the period. AWM Investment Company Inc. owned approximately 0.21% of Progyny worth $4,021,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Progyny in the 1st quarter worth approximately $354,000. Oppenheimer Asset Management Inc. boosted its stake in shares of Progyny by 18.7% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 34,675 shares of the company's stock worth $775,000 after buying an additional 5,459 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Progyny by 233.9% in the 1st quarter. GAMMA Investing LLC now owns 5,379 shares of the company's stock worth $120,000 after purchasing an additional 3,768 shares during the period. Cresset Asset Management LLC bought a new stake in shares of Progyny in the 1st quarter worth approximately $233,000. Finally, Voya Investment Management LLC raised its holdings in shares of Progyny by 1.4% in the 4th quarter. Voya Investment Management LLC now owns 51,792 shares of the company's stock worth $893,000 after purchasing an additional 701 shares during the period. Hedge funds and other institutional investors own 94.93% of the company's stock.

Progyny Stock Performance

PGNY stock traded down $1.01 during midday trading on Friday, reaching $22.55. 978,886 shares of the company's stock traded hands, compared to its average volume of 1,029,759. The company has a 50-day moving average price of $22.94 and a two-hundred day moving average price of $22.23. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $26.76. The firm has a market capitalization of $1.94 billion, a PE ratio of 38.22, a price-to-earnings-growth ratio of 1.84 and a beta of 1.33.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The business had revenue of $332.87 million for the quarter, compared to the consensus estimate of $315.70 million. During the same period in the previous year, the firm earned $0.17 EPS. The company's revenue was up 9.5% compared to the same quarter last year. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. As a group, analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Insider Transactions at Progyny

In other news, Director Cheryl Scott sold 2,675 shares of the company's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total value of $59,037.25. Following the transaction, the director owned 14,112 shares of the company's stock, valued at approximately $311,451.84. This represents a 15.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Allison Swartz sold 2,398 shares of the company's stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $22.96, for a total transaction of $55,058.08. Following the completion of the transaction, the executive vice president directly owned 79,697 shares in the company, valued at approximately $1,829,843.12. The trade was a 2.92% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,570 shares of company stock valued at $238,348. 9.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on PGNY shares. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $28.00 price target (up previously from $26.00) on shares of Progyny in a report on Friday, August 8th. Canaccord Genuity Group lifted their price target on shares of Progyny from $21.00 to $23.00 and gave the stock a "hold" rating in a report on Wednesday, August 20th. JPMorgan Chase & Co. lifted their price target on shares of Progyny from $23.00 to $25.00 and gave the stock a "neutral" rating in a report on Tuesday, August 26th. Truist Financial lifted their price target on shares of Progyny from $24.00 to $27.00 and gave the stock a "hold" rating in a report on Thursday, July 17th. Finally, Raymond James Financial set a $28.00 price target on shares of Progyny in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $25.30.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.